

* The USPTO production files are current through: * * 26 MAR 1996 for U.S. Patent Text Data. *
 * 26 MAR 1996 for U.S. Current Classification data. * * 26 MAR 1996 for U.S. Patent Image Data. *
 * * * * * FILE 'USPAT'

ENTERED AT 09:02:02 ON 01 APR 96

* * * * * WELCOME TO THE *
 * U.S. PATENT TEXT FILE * * * * *
 => s (CR1 or (complement receptor 1)) and (variant? or substitut? or mutein? or mutant?) and 1995-1996/py
 L1 44 (CR1 OR (COMPLEMENT RECEPTOR 1)) AND (VARIANT? OR SUBSTITUT ? O
 R MUTEIN? OR MUTANT?) AND 1995-1996/PY

=> d I1 1-44

1. 5,500,859, **Mar. 19, 1996**, Voice and data transmission system; Raghu Sharma, et al., 370/81, 112, 118 [IMAGE AVAILABLE]
2. 5,496,012, **Mar. 5, 1996**, Industrial roll-up damper; Larry A. Kenny, III, 251/294, 901 [IMAGE AVAILABLE]
3. 5,493,497, **Feb. 20, 1996**, Multiaxis redundant fly-by-wire primary flight control system; Henning Buus, 364/434; 244/194; 318/564 [IMAGE AVAILABLE]
4. 5,493,247, **Feb. 20, 1996**, Gate circuit for hard driven GTO; Horst Gruning, 327/440, 330, 377, 380, 443 [IMAGE AVAILABLE]
5. 5,493,199, **Feb. 20, 1996**, Fast battery charger; Steven E. Koenck, et al., 320/35, 31 [IMAGE AVAILABLE]
6. 5,492,808, **Feb. 20, 1996**, Means for detecting familial colon cancer (FCC); Albert de la Chapelle, et al., 435/6, 91.2; 536/24.3; 935/78 [IMAGE AVAILABLE]
7. 5,483,620, **Jan. 9, 1996**, Learning machine synapse processor system apparatus; Gerald G. Pechanek, et al., 395/27 [IMAGE AVAILABLE]
8. 5,478,728, **Dec. 26, 1995**, Process for antibody combining site-catalyzed SYN elimination in the formation of a CIS olefin; Benjamin F. Cravatt, et al., 435/41, 27, 147, 166, 188.5 [IMAGE AVAILABLE]
9. 5,475,525, **Dec. 12, 1995**, Transverse electrical filter operating optically; Pierre Tournois, et al., 359/245; 250/227.12; 359/259, 301; 372/700 [IMAGE AVAILABLE]
10. 5,474,927, **Dec. 12, 1995**, Complement components and binding ligands in fertility; Deborah J. Anderson, et al., 435/7.21, 806; 436/65, 510, 519, 821, 906 [IMAGE AVAILABLE]
11. 5,472,939, **Dec. 5, 1995**, Method of treating complement mediated disorders; Douglas T. Fearon, et al., 514/8, 2, 12, 885, 886 [IMAGE AVAILABLE]
12. 5,471,470, **Nov. 28, 1995**, Computer-based multifunction personal communications system; Raghu Sharma, et al., 370/81, 112, 118 [IMAGE AVAILABLE]
13. 5,469,365, **Nov. 21, 1995**, Power monitor unit; Jon M. Diekema, et al., 364/483; 340/870.02, 870.03; 364/464.04 [IMAGE AVAILABLE]
14. 5,465,298, **Nov. 7, 1995**, Solid state isolation device using opto-isolators; Dennis E. Wilkison, et al., 379/406, 399, 402, 405, 410 [IMAGE AVAILABLE]
15. 5,461,717, **Oct. 24, 1995**, Apparatus for transferring data between a host device and portable computers of various sizes and for recharging the batteries of same; John Notarianni, et al., 395/750; 361/727, 731; 364/550, DIG.1; 395/892 [IMAGE AVAILABLE]
16. 5,460,945, **Oct. 24, 1995**, Device and method for analysis of blood components and identifying inhibitors and promoters of the inflammatory response; Timothy A. Springer, et al., 435/7.24; 422/58, 69; 427/2.11, 2.13; 435/2, 7.23, 7.8, 29, 30, 174, 176, 177, 240.2, 287.1, 287.2, 287.9, 288.3, 288.5 [IMAGE AVAILABLE]
17. 5,459,798, **Oct. 17, 1995**, System and method of pattern recognition employing a multiprocessing pipelined apparatus with private pattern memory; Delbert D. Bailey, et al., 382/218; 364/231.8, 926.8, 948.34, DIG.1, DIG.2; 382/303 [IMAGE AVAILABLE]
18. 5,456,909, **Oct. 10, 1995**, Glycoform fractions of recombinant soluble **complement** **receptor** **1** (sCR1) having extended half-lives in vivo; Henry C. Marsh, Jr., et al., 424/94.63, 94.64; 435/69.6; 514/8; 530/386 [IMAGE AVAILABLE]

19. 5,455,558, **Oct. 3, 1995**, Automotive turn signal alert device; Albert P. Gregory, 340/474, 475, 477 [IMAGE AVAILABLE]
20. 5,455,165, **Oct. 3, 1995**, Expression vector encoding hybrid immunoglobulins; Daniel J. Capon, et al., 435/69.7, 252.3, 320.1; 536/23.4 [IMAGE AVAILABLE]
21. 5,453,986, **Sep. 26, 1995**, Dual port interface for a computer-based multifunction personal communication system; Jeffrey P. Davis, et al., 370/62, 76; 379/202 [IMAGE AVAILABLE]
22. 5,452,289, **Sep. 19, 1995**, Computer-based multifunction personal communications system; Raghu Sharma, et al., 370/32.1, 81, 112, 118; 379/93 [IMAGE AVAILABLE]
23. 5,451,822, **Sep. 19, 1995**, Electronic control system; Jon H. Bechtel, et al., 307/9.1; 315/82; 359/265, 267 [IMAGE AVAILABLE]
24. 5,450,328, **Sep. 12, 1995**, System for measuring line to ground impedance; Donald R. Janke, et al., 364/482; 324/509, 522, 527, 555; 340/635, 650; 361/42; 364/481, 483, 550 [IMAGE AVAILABLE]
25. 5,448,491, **Sep. 5, 1995**, Monitor for an ungrounded system; Donald R. Janke, et al., 364/483; 324/500, 509; 340/635, 650; 361/42; 364/482, 550, 571.01 [IMAGE AVAILABLE]
26. 5,446,682, **Aug. 29, 1995**, System for calibrating a line isolation monitor; Donald R. Janke, et al., 364/571.01; 324/500, 509; 340/635, 650; 361/42; 364/482, 483, 550 [IMAGE AVAILABLE]
27. 5,446,641, **Aug. 29, 1995**, Power selection and protection circuit responsive to an input voltage for providing series or parallel connected inverters; Jon O. Reynolds, et al., 363/17; 219/137PS; 363/36, 143 [IMAGE AVAILABLE]
28. 5,446,366, **Aug. 29, 1995**, Boost converter power supply with reduced losses, control circuit and method therefor; John A. Bassett, et al., 323/222 [IMAGE AVAILABLE]
29. 5,444,155, **Aug. 22, 1995**, Molecules with antibody combining sites that induce asymmetry; Kim Janda, et al., 530/388.1; 435/135, 146, 188.5, 196, 240.26, 240.27; 530/387.1 [IMAGE AVAILABLE]
30. 5,442,153, **Aug. 15, 1995**, High velocity electric-arc spray apparatus and method of forming materials; Daniel R. Marantz, et al., 219/121.47, 76.16, 121.5, 121.52, 121.59 [IMAGE AVAILABLE]
31. 5,442,049, **Aug. 15, 1995**, Oligonucleotides for modulating the effects of cytomegalovirus infections; Kevin Anderson, et al., 536/24.5 [IMAGE AVAILABLE]
32. 5,441,340, **Aug. 15, 1995**, Method for controlling the density of a well fracturing slurry; Greg Cedillo, et al., 366/2; 166/308; 366/17, 20, 152.2 [IMAGE AVAILABLE]
33. 5,440,021, **Aug. 8, 1995**, Antibodies to human IL-8 type B receptor; Anan Chuntharapai, et al., 530/388.22; 435/240.27; 530/388.23, 389.1, 389.2 [IMAGE AVAILABLE]
34. 5,429,941, **Jul. 4, 1995**, Process for antibody combining site-catalyzed epoxide formation from 1-benzyl-1-hydrocarbyl alkene molecules; Richard A. Lerner, et al., 435/123, 188.5 [IMAGE AVAILABLE]
35. 5,428,130, **Jun. 27, 1995**, Hybrid immunoglobulins; Daniel J. Capon, et al., 530/350; 435/69.7; 530/387.1; 536/23.4 [IMAGE AVAILABLE]
36. 5,426,029, **Jun. 20, 1995**, Therapeutic and diagnostic methods using leukocyte surface antigens; Charles W. Rittershaus, et al., 435/7.21, 7.24, 7.9, 7.94; 436/501, 506, 518, 536 [IMAGE AVAILABLE]
37. 5,418,246, **May 23, 1995**, Oxa(thia)diazol- and triazol-ones(thiones) having a miticide and insecticide activity; Franco Bettarini, et al., 514/364; 548/136, 144, 263.2 [IMAGE AVAILABLE]
38. 5,408,173, **Apr. 18, 1995**, Manual-adjustment-free controlled-voltage and current-limited D.C. voltage supply; Herbert C. Knapp, 323/285, 282; 363/79 [IMAGE AVAILABLE]
39. 5,403,713, **Apr. 4, 1995**, Antibodies specific for ELAM-1 and the use thereof; Michael P. Bevilacqua, et al., 435/7.1; 424/152.1, 153.1; 436/504, 512; 530/388.22, 391.3 [IMAGE AVAILABLE]
40. 5,402,168, **Mar. 28, 1995**, Multi-standard observation camera and a surveillance system using the camera; Jean-Pierre Fouilloy, 348/164, 295 [IMAGE AVAILABLE]
41. 5,393,067, **Feb. 28, 1995**, System, method and apparatus for generating large jackpots on live game card tables; Craig A. Paulsen, et al., 273/292; 194/239; 273/309 [IMAGE AVAILABLE]

42. 5,384,678, **Jan. 24, 1995**, Control and self-monitoring system, in particular for a multipole electrical apparatus such as a high tension circuit breaker; Gerard Ebersohl, et al., 361/62, 64, 66, 97 [IMAGE AVAILABLE]

43. 5,384,252, **Jan. 24, 1995**, Molecules with antibody combining sites that catalyze carbocyclic ring formation from 5,6-ethylenically unsaturated sulfonate molecules; Kim Janda, 435/166, 188.5, 240.27 [IMAGE AVAILABLE]

44. 5,378,464, **Jan. 3, 1995**, Modulation of inflammatory responses by administration of GMP-140 or antibody to GMP-140; Rodger P. McEver, 424/143.1; 514/8 [IMAGE AVAILABLE]

= > d l1 10,11,16,18 ab

US PAT NO: 5,474,927 [IMAGE AVAILABLE] L1: 10 of 44

ABSTRACT:

Methods for detecting and isolating acrosome-reacted sperm and complement receptor-bearing oocytes using the complement component C3, fragments, or **variants** thereof, antibodies to a complement receptor, or antibodies to C3, are disclosed. These methods have application in the assessment of fertility, in the preparation of sperm or oocytes for in vitro fertilization or for gamete intrafallopian tube transfer, in promoting or inhibiting fertilization in vitro and in vivo, and in diagnosing and treating infertility.

US PAT NO: 5,472,939 [IMAGE AVAILABLE] L1: 11 of 44

ABSTRACT:

The present invention relates to the C3b/C4b receptor (**CR1**) gene and its encoded protein. The invention also relates to **CR1** nucleic acid sequences and fragments thereof comprising 70 nucleotides and their encoded peptides or proteins comprising 24 amino acids. The invention further provides for the expression of the **CR1** protein and fragments thereof. The genes and proteins of the invention have uses in diagnosis and therapy of disorders involving complement activity, and various immune system or inflammatory disorders. In specific embodiments of the present invention detailed in the examples sections infra, the cloning, nucleotide sequence, and deduced amino acid sequence of a full-length **CR1** cDNA and fragments thereof are described. The expression of the **CR1** protein and fragments thereof is also described. Also described is the expression of a secreted **CR1** molecule lacking a transmembrane region. The secreted **CR1** molecule is shown to be useful in reducing damage caused by inflammation and in reducing myocardial infarct size and preventing reperfusion injury.

US PAT NO: 5,460,945 [IMAGE AVAILABLE] L1: 16 of 44

ABSTRACT:

The present invention provides in vitro models of the in vivo rolling and arrest of leukocytes along the endothelial cell wall, which are important steps in the migration of leukocytes out of the blood stream and into tissue, as part of the inflammatory response. The in vitro models of the invention are functional under physiologic flow conditions resulting in physiologic shear stresses. In a specific embodiment, for modelling leukocyte rolling, the apparatus of the invention comprises a solid phase surface with rolling mediator molecules present thereon. Such rolling mediators are, for example, selectins and selectin ligands which have binding partners expressed on leukocytes. In another specific embodiment, for modelling leukocyte rolling followed by adhesion/arrest, the apparatus of the invention comprises a solid phase surface with both rolling mediators and integrin binding partners present thereon. The apparatuses of the invention can be used for collecting, concentrating, purifying, and analyzing blood and blood components, in particular, leukocytes and subsets thereof. The invention further relates to methods for identifying inhibitors or, alternatively, promoters (agonists, functional components) of the inflammatory response. Therapeutic and diagnostic methods, pharmaceutical compositions and kits are also provided.

US PAT NO: 5,456,909 [IMAGE AVAILABLE] L1: 18 of 44

ABSTRACT:

The present invention relates to novel glycoforms and preparations of the soluble complement receptor type 1 (sCR1), and their uses in the therapy of complement mediated diseases and disorders involving inflammation and inappropriate complement activation and in thrombotic or shock state conditions. The invention provides novel glycoforms and methods for producing, detecting, enriching and purifying such glycoforms. The invention further provides methods of specifically producing a glycoform by recombinant or chemical means. Preferred embodiments of the invention include sialylated glycoforms and glycoforms with a pl.toreq.5.1 determined by chromatofocusing or with a sialic acid to mannose molar ratio of >0.25. The glycoforms may be formulated alone in therapeutic compositions or in combination with thrombolytic agents.

= > log y

U.S. Patent & Trademark Office LOGOFF AT 09:09:05 ON 01 APR 96

++ +

OK

ATH

OK